期刊文献+

甲状旁腺素通过磷脂酶C非依赖途径激活蛋白激酶C 被引量:3

Parathyroid hormone activates protein kinase C via phospholipase C-independent signaling pathway
下载PDF
导出
摘要 目的利用基于荧光共振能量转移(Fluorescence resonance energy transfer,FRET)技术的检测PKC激活或PKC-delta激活的报告分子来确定PTH是否可以通过PLC非依赖途径激活PKC和PKC-delta。方法将表达PKC激活报告分子(CKAR)的质粒和表达PKC-delta激活报告分子的质粒转染HEK293细胞,培养72h后通过共聚焦显微镜检测FRET的改变,并以此判断佛波酯(TPA)是否激活PKC和PKC-delta。将表达甲状旁腺素1型受体(PTHR1)的质粒与CKAR质粒或PKC-delta质粒共转染HEK293细胞,培养72h后通过共聚焦显微镜检测FRET的改变,并判断PTH(1-34)、G1R19(1-34)和0.1%的三氟乙酸(TFA)对PKC和PKC-delta的作用。结果在转染CKAR质粒或PKC-delta质粒的HEK293细胞,TPA均使青色荧光与黄色荧光的强度之比(C/Y)增加。在共转染PTH1R质粒与CKAR质粒或PKC-delta质粒的HEK293细胞,PTH(1-34)和G1R19(1-34)均增加了C/Y的值,而0.1%TFA未引起C/Y的改变。结论 PTH与PTHR1结合后通过PLC非依赖途径激活PKC/PKC-delta。 Objective To determine whether PTH activates PKC/PKC-delta via PLC-independent pathway using the reporter of PKC or PKC-delta activation based on fluorescence resonance energy transfer(FRET).Methods HEK293 cells were transfected with C kinase activity reporter(CKAR) or C-delta kinase activity reporter(PKC-delta).After incubation for 72h,FRET was measured with or without stimulation of phorbol esters(TPA).The activation of PKC or PKC-delta could be judged by the change in FRET.HEK293 cells were co-transfected with either CKAR or PKC-delta plasmid or PTHR1 plasmid.Stimulation of PKC or PKC-delta by PTH(1-34) or G1R19(1-34) or 0.1% trifluoroacetic acid(TFA) were demonstrated by monitoring the change in FRET after 72 h.Results TPA increased the CFP/YFP emission ratio(C/Y) in HEK293 cells transfected with CKAR or PKC-delta plasmid.PTH(1-34) and G1R19(1-34),but not 0.1% TFA,increased C/Y in HEK293 cells co-transfected with either CKAR or PKC-delta plasmid or PTHR1 plasmid.Conclusion PTH binding to PTHR1 can activate PKC and PKC-delta via PLC-independent signaling pathway.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2012年第4期295-299,共5页 Chinese Journal of Osteoporosis
基金 广东省自然科学基金项目(9151051501000087) 国家自然科学基金(30973061)
关键词 甲状旁腺素 荧光共振能量转移 PKC激活报告分子 PKC-delta激活报告分子 甲状旁腺素1型受体 Parathyroid hormone Fluorescence resonance energy transfer C kinase activity reporter C-delta kinase activity reporter Type Ⅰ PTH receptor
  • 相关文献

参考文献19

  • 1Rey A,Manen D,Rizzoli R,et al.Evidences for a role of p38MAP kinase in the stimulation of alkaline phosphatase and matrixmineralization induced by parathyroid hormone in osteoblasticcells.Bone,2007,41(1):59-67.
  • 2Shimizu M,Carter PH,Khatri A,et al.Enhanced activity inparathyroid hormone-(1-14)and-(1-11):novel peptides forprobing ligand-receptor interactions.Endocrinology,2001,142(7):3068-74.
  • 3Verhaar HJ,Lems WF.PTH-analogs:comparable or different?Arch Gerontol Geriatr,2009,49(2):e130-2.
  • 4Jeon J.H.,Puleo D.A.Alternating release of different bioactivemolecules from a complexation polymer system.Biomaterials,2008,29(26):3591-8.
  • 5Pettway GJ,Schneider A,Koh AJ,et al.Anabolic actions of PTH(1-34):use of a novel tissue engineering model to investigatetemporal effects on bone.Bone,2005,36(6):959-70.
  • 6Valenta A,Roschger P,Fratzl-Zelman N,et al.Combinedtreatment with PTH(1-34)and OPG increases bone volume anduniformity of mineralization in aged ovariectomized rats.Bone,2005,37(1):87-95.
  • 7Wang YH,Liu Y,Rowe DW.Effects of transient PTH on earlyproliferation,apoptosis,and subsequent differentiation ofosteoblast in primary osteoblast cultures.Am J Physiol EndocrinolMetab,2007,292(2):E594-603.
  • 8Rickard DJ,Wang FL,Rodriguez-Rojas AM,et al.Intermittenttreatment with parathyroid hormone(PTH)as well as a non-peptide small molecule agonist of the PTH1 receptor inhibitsadipocyte differentiation in human bone marrow stromal cells.Bone,2006,39(6):1361-72.
  • 9Takasu H,Guo J,Bringhurst FR.Dual signaling and ligandselectivity of the human PTH/PTHrP receptor.J Bone Miner Res,1999,14(1):11-20.
  • 10Yang D,Guo J,Divieti P,et al.Parathyroid hormone activatesPKC-delta and regulates osteoblastic differentiation via a PLC-independent pathway.Bone,2006,38(4):485-96.

同被引文献27

  • 1邱贵兴.骨质疏松性骨折——被忽视了的健康杀手[J].中华医学杂志,2005,85(11):730-731. 被引量:76
  • 2Cosman F. Parathyroid hormone treatment for osteoporosis [J]. Curr Opin Endocrinol Diabetes Obes, 2008, 15 (6) : 495-501.
  • 3Thomas T. Intermittent parathyroid hormone therapy to increase bone formation [J]. Joint Bone Spine, 2006, 73 (3) : 262-269.
  • 4Paschalis EP, Glass EV, Donley DW, et al. Bone mineral and col- lagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trim [J]. J Clin Endocrinol Metab, 2005, 90 (8): 4644-4649.
  • 5Miyauchi A, Matsumoto T, Shigeta H, et al. Effect of teriparatide on bone mineral density and biochemical markers in Japanese womenwith postmenopausal osteoporosis: a 6-month dose-response study [J]. J Bone Miner Metab, 2008, 26 (6) : 624-634.
  • 6Neer RM, Amaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post- menopausal women with osteoporosis [J]. N Engl J Med, 2001, 344 (19): 1434-1441.
  • 7Eastell R, Nickelsen T, Matin F, et al. Sequential treatment of se- vere postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EURO- FORS)[J]. J Bone Miner Res, 2009, 24 (4) : 726-736.
  • 8Kung AW, Pasion EG, Sofiyan M, et el. A comparison of teri- paratide and celcitonin therapy in postmenopausal Asian women with osteoporosis: a6-month study [J]. Curr Med Res Opin, 2006, 22 (5) : 929-937.
  • 9Hwang JS, Tu ST, Yang TS, et el. Teriparatide vs. celcitonin in the treatment of Asian postmenopausel women with established osteo- porosis [Jl. Osteoporos Int, 2006, 17 (3) : 373-378.
  • 10Andrews EB, Gilsenan AW, MidkiffK, et al. The US postmarket- ing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years [J]. J Bone Miner Res, 2012, 27 (12): 2429-2437.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部